Across TCGA pan-cancer cohorts, TRMT2B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRMT2B data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRMT2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRMT2B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where TRMT2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.285	0.722	.010	9	view →
LSCC	DFS	Tertile	III,IV	0.452	1.000	.044	8	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.709	.022	6	view →
LUAD	OS	Quartile	II,III,IV	0.884	0.394	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TRMT2B tumor-vs-normal RNA expression · all TRMT2B data types